VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Recombinant spike polypeptide vaccine
Vaccine Information
  • Vaccine Name: Recombinant spike polypeptide vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: intraperitoneal recombinant spike polypeptide generated by amplify gene encoding amino acids residues 14-667 of S protein that was cloned BamHI and KpnI sites of vector pQE-31 that was generated by Escherichia coli (Woo et al., 2005)
Host Response

Mouse Response

  • Host Strain: Balb/c (H-2d)
  • Host age: 6-8 weeks (Woo et al., 2005)
  • Host gender: Male (Woo et al., 2005)
  • Vaccination Protocol: 50 μg administered via intraperitoneal route on days 0, 14, and 28. (Woo et al., 2005)
  • Immune Response: No neutralizing antibody production, high IgG levels, lymphocyte proliferation, production of IFN-γ >6000 pg/ml at 48hrs and 72hrs, detectable production of IL-4 at 24hrs (Woo et al., 2005)
References
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].